Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Calquence<sup>®</sup> (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug–drug...

Full description

Bibliographic Details
Main Authors:	Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Nishant Biswas, Molly S. Adam, Adam Smith, Christopher D. Craig, Michael M. Morgen, David T. Vodak
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Pharmaceutics
Subjects:	acalabrutinib amorphous solid dispersion acid-reducing agent bioavailability enhancement kinase inhibitor pH effect
Online Access:	https://www.mdpi.com/1999-4923/13/4/557

Similar Items

In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets
by: Deanna M. Mudie, et al.
Published: (2021-08-01)

Correction: Mudie et al. In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets. <i>Pharmaceutics</i> 2021, <i>13</i>, 1257
by: Deanna M. Mudie, et al.
Published: (2021-12-01)

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
by: LIANG Cuilyu, et al.
Published: (2022-11-01)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
by: Jari M. Tuomi, et al.
Published: (2021-11-01)

Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review
by: Peihao Zheng, et al.
Published: (2025-02-01)

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis
by: Joachim Alexandre, et al.
Published: (2025-03-01)

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
by: Thura Win Htut, et al.
Published: (2022-05-01)

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib
by: Diamond R. Guy, BS, et al.
Published: (2024-05-01)

Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib – Case report
by: Aisling Barrett, et al.
Published: (2024-02-01)

An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
by: Mohamed W. Attwa, et al.
Published: (2023-10-01)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
by: Surendra Poudel, et al.
Published: (2021-04-01)

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report
by: Anna Nikkarinen, et al.
Published: (2024-08-01)

Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
by: Sathish Dharani, et al.
Published: (2022-11-01)

Spray-dried co-amorphous Tadalafil ternary mixtures: a promising platform towards the enhancement of solubility and bioavailability
by: Hoda El-Maradny, et al.
Published: (2023-01-01)

Enhancing hepatoprotective action: oxyberberine amorphous solid dispersion system targeting TLR4
by: Tingting Chen, et al.
Published: (2024-06-01)

Polymer–Surfactant System Based Amorphous Solid Dispersion: Precipitation Inhibition and Bioavailability Enhancement of Itraconazole
by: Disang Feng, et al.
Published: (2018-04-01)

Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature
by: Bowen He, et al.
Published: (2023-09-01)

Development of a Novel Co-Amorphous Curcumin and L-Arginine (1:2): Structural Characterization, Biological Activity and Pharmacokinetics
by: Jose Antonio Mancillas-Quiroz, et al.
Published: (2024-12-01)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
by: Seo-Yeon Kim, et al.
Published: (2023-09-01)

Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy
by: S. K. Zyryanov, et al.
Published: (2024-08-01)

Amorphous semiconductors /
by: Brodsky, M. H.
Published: (1985)

Amorphous semiconductors /
by: Brosdsky, M. H.
Published: (1979)

Amorphous semiconductor technologies & devices /
by: Hamakawa, Y.
Published: (1984)

Amorphous materials issue IX/
by: Tohoku University. Research Institutes, et al.
Published: (1988)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
by: Jia Liu, et al.
Published: (2022-09-01)

Molecular Simulation and Statistical Learning Methods toward Predicting Drug–Polymer Amorphous Solid Dispersion Miscibility, Stability, and Formulation Design
by: Daniel M. Walden, et al.
Published: (2021-01-01)

Development and Characterization of an Amorphous Solid Dispersion of Furosemide in the Form of a Sublingual Bioadhesive Film to Enhance Bioavailability
by: Viviana De Caro, et al.
Published: (2017-06-01)

The baicalein amorphous solid dispersion to enhance the dissolution and bioavailability and effects on growth performance, meat quality, antioxidant capacity and intestinal flora in Taihang chickens
by: Jianting Gao, et al.
Published: (2024-07-01)

Tetrahedrally bonded amorphous semiconductors /
by: International Conference on Tetrahedrally Bonded Semiconductors (1974 : New York), et al.
Published: (1974)

Recent Technologies for Amorphization of Poorly Water-Soluble Drugs
by: Dohyun Kim, et al.
Published: (2021-08-01)

Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans
by: Andreas Schittny, et al.
Published: (2021-03-01)

Physics of amorphous materials /
by: Elliott, S. R. (Stephen Richard), 1952-
Published: (1983)

Advances in amorphous semiconductors /
by: 188141 Singh, Jai, et al.
Published: (2003)

Bioavailability Improvement of Carbamazepine via Oral Administration of Modified-Release Amorphous Solid Dispersions in Rats
by: Houli Li, et al.
Published: (2020-10-01)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
by: Vincenzo Nasillo, et al.
Published: (2022-03-01)

Amorphous materials : modeling of structure and properties
Published: (1983)

Physics and applications of amorphous semiconductors/
by: International Symposium on Physics and Applications of Amorphous Semiconductors (1st: 1987: Torino), et al.
Published: (1988)

Structure and excitations of amorphous solids/
by: International Conference on Structure and Excitations of Amorphous Solids (1976: Virginia), et al.
Published: (1976)

Amorphous semiconductors '76 : proceedings /
by: International Conference on Amorphous Semiconductors 1976 (1976 : Balatonfured, Hungray), et al.
Published: (1977)

Magnetic properties of amorphous metals /
by: Symposium on Magnetic Properties of Amorphous Metals (1987 : Benalmadena, Spain), et al.
Published: (1987)